StockData
Palvella Therapeutics, Inc. logo

Palvella Therapeutics, Inc. (PVLA) stock

PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$144.35−0.25 (-0.17%)

Close on Nov 17, 2026Market cap $2.08BP/E –Yield –

Palvella Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Palvella Therapeutics's total assets was $253.51M at Jun 30, 2026. For fiscal 2025 it was $59.56M, down 32.5% from the year before. Over ten years it grew 5.8% a year on average. The highest annual figure on record is $153.56M in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$59.56M-32.5%
FY2024Dec 31, 2024$88.23M+1069.0%
FY2023Dec 31, 2023$7.55M-92.1%
FY2022Dec 31, 2022$95.49M-37.8%
FY2021Dec 31, 2021$153.56M+46.2%
FY2020Dec 31, 2020$105.01M-25.6%
FY2019Dec 31, 2019$141.10M-0.2%
FY2018Dec 31, 2018$141.34M+36.1%
FY2017Dec 31, 2017$103.88M+196.3%
FY2016Dec 31, 2016$35.06M+3.3%
FY2015Dec 31, 2015$33.95M+55.3%
FY2014Dec 31, 2014$21.86M+200.4%
FY2013Dec 31, 2013$7.28M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$253.51M+243.8%
Q1 FY2026Mar 31, 2026$263.76M+232.0%
Q4 FY2025Dec 31, 2025$59.56M-32.5%
Q3 FY2025Sep 30, 2025$66.94M+226.2%
Q2 FY2025Jun 30, 2025$73.75M+194.4%
Q1 FY2025Mar 31, 2025$79.44M+169.3%
Q4 FY2024Dec 31, 2024$88.23M+1069.0%
Q3 FY2024Sep 30, 2024$20.52M-65.4%
Q2 FY2024Jun 30, 2024$25.05M-71.4%
Q1 FY2024Mar 31, 2024$29.50M-64.1%
Q4 FY2023Dec 31, 2023$7.55M-92.1%
Q3 FY2023Sep 30, 2023$59.38M-40.1%
Q2 FY2023Jun 30, 2023$87.54M-23.4%
Q1 FY2023Mar 31, 2023$82.26M-40.0%
Q4 FY2022Dec 31, 2022$95.49M-37.8%
Q3 FY2022Sep 30, 2022$99.16M-39.6%
Q2 FY2022Jun 30, 2022$114.31M-26.3%
Q1 FY2022Mar 31, 2022$137.12M+18.4%
Q4 FY2021Dec 31, 2021$153.56M+46.2%
Q3 FY2021Sep 30, 2021$164.18M+41.9%
Q2 FY2021Jun 30, 2021$155.03M+31.6%
Q1 FY2021Mar 31, 2021$115.79M-6.5%
Q4 FY2020Dec 31, 2020$105.01M-25.6%
Q3 FY2020Sep 30, 2020$115.72M-0.9%
Q2 FY2020Jun 30, 2020$117.78M-10.0%
Q1 FY2020Mar 31, 2020$123.77M-5.6%
Q4 FY2019Dec 31, 2019$141.10M-0.2%
Q3 FY2019Sep 30, 2019$116.75M-23.0%
Q2 FY2019Jun 30, 2019$130.84M-19.2%
Q1 FY2019Mar 31, 2019$131.05M-24.4%
Q4 FY2018Dec 31, 2018$141.34M+36.1%
Q3 FY2018Sep 30, 2018$151.66M+53.4%
Q2 FY2018Jun 30, 2018$162.03M+52.9%
Q1 FY2018Mar 31, 2018$173.24M+180.0%
Q4 FY2017Dec 31, 2017$103.88M+196.3%
Q3 FY2017Sep 30, 2017$98.86M+126.2%
Q2 FY2017Jun 30, 2017$105.96M–
Q1 FY2017Mar 31, 2017$61.88M–
Q4 FY2016Dec 31, 2016$35.06M–
Q3 FY2016Sep 30, 2016$43.71M–

More Palvella Therapeutics figures

See a number that looks wrong?